Author: Daga, S.; Fallerini, C.; Baldassarri, M.; Fava, F.; Valentino, F.; Doddato, G.; Benetti, E.; Furini, S.; Giliberti, A.; Tita, R.; Amitrano, S.; Bruttini, M.; Meloni, I.; Pinto, A. M.; Raimondi, F.; Stella, A.; Biscarini, F.; Picchiotti, N.; Gori, M.; Pinoli, P.; Ceri, S.; Sanarico, M.; Crawley, F. P.; GEN-COVID Multicenter Study,; Renieri, A.; Mari, F.; Frullanti, E.
Title: Employing a Systematic Approach to Biobanking and Analyzing Genetic and Clinical Data for Advancing COVID-19 Research Cord-id: k1rgljmu Document date: 2020_7_24
ID: k1rgljmu
Snippet: Within the GEN-COVID Multicenter Study, biospecimens from more than 1,000 SARS-CoV-2-positive individuals have thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum, leukocytes, and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O2 supplementation, and without respiratory support (9.
Document: Within the GEN-COVID Multicenter Study, biospecimens from more than 1,000 SARS-CoV-2-positive individuals have thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum, leukocytes, and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O2 supplementation, and without respiratory support (9.5%, 18.4%, 31.55% and 14.8, respectively); and non-hospitalized subjects (25.75%), either pauci- or asymptomatic. More than 150 clinical patient-level data fields have been collected and binarized according to the organs/systems primarily affected by COVID-19: heart, liver, pancreas, kidney, chemosensors, innate or adaptive immunity, and clotting system, for further statistics. Hierarchical Clustering analysis identified five main clinical categories: i) severe multisystemic failure with either thromboembolic or pancreatic variant; ii) cytokine storm type either severe with liver involvement or moderate; iii) moderate heart type either with or without liver damage; iv) moderate multisystemic involvement either with or without liver damage; v) mild either with or without hyposmia. GCB and GCPR are further linked to the GEN-COVID Genetic Data Repository (GCGDR), which includes data from Whole Exome Sequencing and high-density SNP genotyping. The data are available for sharing through the Network for Italian Genomes, within the COVID-19 dedicated section. The study objective is to systematize this comprehensive data collection and start identifying multi-organ involvement in COVID-19, defining genetic parameters for infection susceptibility within the population, and mapping genetically COVID-19 severity and clinical complexity among patients.
Search related documents:
Co phrase search for related documents- acute coronavirus sars respiratory syndrome and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute coronavirus sars respiratory syndrome and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute coronavirus sars respiratory syndrome and liver enzyme elevation: 1, 2, 3, 4
- acute coronavirus sars respiratory syndrome and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute coronavirus sars respiratory syndrome and liver involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute coronavirus sars respiratory syndrome and low frequency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute coronavirus sars respiratory syndrome and low frequency variant: 1
- acute coronavirus sars respiratory syndrome and lung disorder: 1, 2, 3, 4, 5
- acute coronavirus sars respiratory syndrome and lung dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- admission time and liver damage: 1, 2, 3, 4, 5, 6
- admission time and liver enzyme: 1, 2, 3
- admission time and liver enzyme elevation: 1
- admission time and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- admission time and liver involvement: 1, 2, 3, 4, 5
- admission time and low frequency: 1
- admission time and lung disorder: 1
- admission time and lung dysfunction: 1, 2
- liver damage and low frequency: 1
- liver damage and lung dysfunction: 1, 2
Co phrase search for related documents, hyperlinks ordered by date